Optimized preparation and preliminary evaluation of [64Cu]–DOTA–trastuzumab for targeting ErbB2/Neu expression

Breast cancer radioimmunoscintigraphy targeting HER2/neu expression is a growing field of work in nuclear medicine research. Trastuzumab is a monoclonal antibody that binds with high affinity to HER2/neu, which is over expressed on breast and other tumors. Developing new tracers for the detection of this cancer is of great interest. In this study, trastuzumab was successively labeled with [⁶⁴Cu]CuCl₂ after conjugation with DOTA-NHS-ester. The conjugate was purified by molecular filtration, the average number of DOTA conjugated per mAb was calculated and total concentration was determined by spectrophotometric method. DOTA–trastuzumab was labeled with ⁶⁴Cu produced by ⁶⁸Zn(p,αn)⁶⁴Cu nuclear reaction (30 MeV protons at 180 μA). Radiochemical purity, integrity of protein after radiolabeling and immunoreactivity of radiolabeled mAb trastuzumab with HER2/neu antigen and SkBr3 cell line were performed by RIA. In vitro stability of radiolabeled mAb in human serum was determined by thin layer chromatography. In vitro internalization studies were performed with the SkBr3 cell line and the tissue biodistribution of the ⁶⁴Cu–DOTA–trastuzumab was evaluated in wild-type rat (90 ± 5.5 μCi, 2, 6, 12, 24 h p.i.). The radioimmunoconjugate was prepared with a radiochemical purity of higher than 96 ± 0.5 % (ITLC) and specific activity as high as 5.3 μCi/μg. The average number of chelators per antibody for the conjugate used in this study was 5.8/1. The sample was showed to have similar patterns of migration in the gel electrophoresis. The ⁶⁴Cu–DOTA–trastuzumab showed high immunoreactivity towards HER2/neu antigen and SkBr3 cell line. In vitro stability of the labeled product was found to be more than 94 % in PBS and 82 ± 0.5 % in human serum over 48 h. In vitro internalization studies of the ⁶⁴Cu–DOTA–trastuzumab showed that up to 11.5 % of the radioimmunoconjugate internalized after 10 h. The accumulation of the radiolabeled mAb in liver, skin, intestine, lung, spleen, kidney and other tissues demonstrates a similar pattern to the other radiolabeled anti-HER2 immunoconjugates. ⁶⁴Cu–DOTA–trastuzumab is a potential compound for molecular imaging of PET for diagnosis and treatment studies and follow-up of HER2 expression in oncology.     

The Synthesis and Initial Evaluation of MerTK Targeted PET Agents

MerTK (Mer tyrosine kinase), a receptor tyrosine kinase, is ectopically or aberrantly expressed in numerous human hematologic and solid malignancies. Although a variety of MerTK targeting therapies are being developed to enhance outcomes for patients with various cancers, the sensitivity of tumors to MerTK suppression may not be uniform due to the heterogeneity of solid tumors and different tumor stages. In this report, we develop a series of radiolabeled agents as potential MerTK PET (positron emission tomography) agents. In our initial in vivo evaluation, [¹⁸F]-MerTK-6 showed prominent uptake rate (4.79 ± 0.24%ID/g) in B16F10 tumor-bearing mice. The tumor to muscle ratio reached 1.86 and 3.09 at 0.5 and 2 h post-injection, respectively. In summary, [¹⁸F]-MerTK-6 is a promising PET agent for MerTK imaging and is worth further evaluation in future studies.     

Chelation of Theranostic Copper Radioisotopes with S-Rich Macrocycles: From Radiolabelling of Copper-64 to In Vivo Investigation

Copper radioisotopes are generally employed for cancer imaging and therapy when firmly coordinated via a chelating agent coupled to a tumor-seeking vector. However, the biologically triggered Cu²⁺-Cu⁺ redox switching may constrain the in vivo integrity of the resulting complex, leading to demetallation processes. This unsought pathway is expected to be hindered by chelators bearing N, O, and S donors which appropriately complements the borderline-hard and soft nature of Cu²⁺ and Cu⁺. In this work, the labelling performances of a series of S-rich polyazamacrocyclic chelators with [⁶⁴Cu]Cu²⁺ and the stability of the [⁶⁴Cu]Cu-complexes thereof were evaluated. Among the chelators considered, the best results were obtained with 1,7-bis [2-(methylsulfanyl)ethyl]-4,10,diacetic acid-1,4,7,10-tetraazacyclododecane (DO2A2S). DO2A2S was labelled at high molar activities in mild reaction conditions, and its [⁶⁴Cu]Cu²⁺ complex showed excellent integrity in human serum over 24 h. Biodistribution studies in BALB/c nude mice performed with [⁶⁴Cu][Cu(DO2A2S)] revealed a behavior similar to other [⁶⁴Cu]Cu-labelled cyclen derivatives characterized by high liver and kidney uptake, which could either be ascribed to transchelation phenomena or metabolic processing of the intact complex.     

Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals

The molecules known as bis(thiosemicarbazones) derived from 1,2-diones can act as tetradentate ligands for Cu(II), forming stable, neutral complexes. As a family, these complexes possess fascinating biological activity. This critical review presents an historical perspective of their progression from potential chemotherapeutics through to more recent applications in nuclear medicine. Methods of synthesis are presented followed by studies focusing on their potential application as anti-cancer agents and more recent investigations into their potential as therapeutics for Alzheimer's disease. The Cu(II) complexes are of sufficient stability to be used to coordinate copper radioisotopes for application in diagnostic and therapeutic radiopharmaceuticals. Detailed understanding of the coordination chemistry has allowed careful manipulation of the metal based properties to engineer specific biological activities. Perhaps the most promising complex radiolabelled with copper radioisotopes to date is Cu(II)(atsm), which has progressed to clinical trials in humans (162 references).     

Enzyme‐Mediated Site‐Specific Bioconjugation of Metal Complexes to Proteins: Sortase‐Mediated Coupling of Copper‐64 to a Single‐Chain Antibody

The enzyme‐mediated site‐specific bioconjugation of a radioactive metal complex to a single‐chain antibody using the transpeptidase sortase A is reported. Cage amine sarcophagine ligands that were designed to function as substrates for the sortase A mediated bioconjugation to antibodies were synthesized and enzymatically conjugated to a single‐chain variable fragment. The antibody fragment scFv_anti‐LIBS targets ligand‐induced binding sites (LIBS) on the glycoprotein receptor GPIIb/IIIa, which is present on activated platelets. The immunoconjugates were radiolabeled with the positron‐emitting isotope ⁶⁴Cu. The new radiolabeled conjugates were shown to bind selectively to activated platelets. The diagnostic potential of the most promising conjugate was demonstrated in an in vivo model of carotid artery thrombosis using positron emission tomography. This approach gives homogeneous products through site‐specific enzyme‐mediated conjugation and should be broadly applicable to other metal complexes and proteins.     

Separation of carrier-free 64,67Cu radionuclides from irradiated zinc targets using 6-tungstocerate(IV) gel matrix

Summary A procedure for the separation of ^64,67Cu radioisotopes from irradiated natural zinc targets was developed. Production of ^64,67Cu was carried out using ^64,67Zn(n,p)^64,67Cu reactions by fast neutron bombardment of natural zinc targets at The Second Egyptian Research Reactor (ETRR-2). The sorption behavior of ⁶⁵Zn and ^64,67Cu ions in HCl acid solutions showed high affinity of Cu ions towards 6-tungstocerate(IV) gel matrix compared with Zn ions. Carrier-free ^64,67Cu radionuclides were separated from ⁶⁵Zn on 6-tungstocerate(IV) column matrix by eluting the column with 10 ml 0.001 and 1M HCl acid solutions. The separated ^64,67Cu radionuclides were of high chemical, radiochemical and radionuclidic purity.     

Application of radiotracers with high specific radioactivity to metallotoxicological studies

The use of radiotracers with high specific activity in research on health impact of trace metals overcomes many of the analytical difficulties associated with experimentation carried out at metal levels which are typical of the polluted environment. It allows one to detect and measure ultratrace amounts of metals in biological samples and to follow them into different biochemical compartments, such as subcellular fractions and molecular components. This work shows typical examples of metallotoxicological studies carried out at the JRC-Ispra using radioisotopes with high specific radiactivity produced in the nuclear reactor and in the cyclotron. Applications refer to the use of⁴⁵Ti,⁴⁸V,⁶⁴Cu,⁹⁵Nb and^106mAg in in-vivo and in-vitro studies related to environmental and occupational toxicology research on trace metals.     

A Cyclen‐Based Tetraphosphinate Chelator for the Preparation of Radiolabeled Tetrameric Bioconjugates

The cyclen‐based tetraphosphinate chelator 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetrakis[methylene(2‐carboxyethyl)phosphinic acid] (DOTPI) comprises four additional carboxylic acid moieties for bioconjugation. The thermodynamic stability constants (logK_ML) of metal complexes, as determined by potentiometry, were 23.11 for Cu^II, 20.0 for Lu^III, 19.6 for Y^III, and 21.0 for Gd^III. DOTPI was functionalized with four cyclo(Arg‐Gly‐Asp‐D ‐Phe‐Lys) (RGD) peptides through polyethylene glycol (PEG₄) linkers. The resulting tetrameric conjugate DOTPI(RGD)₄ was radiolabeled with ¹⁷⁷Lu and ⁶⁴Cu and showed improved labeling efficiency compared with 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid (DOTA). The labeled compounds were fully stable in transchelation challenges against trisodium diethylenetriaminepentaacetate (DTPA) and disodium ethylenediaminetetraacetic acid (ETDA), in phosphate buffered saline (PBS), and human plasma. Integrin α_vβ₃ affinities of the non‐radioactive Lu^III and Cu^II complexes of DOTPI(RGD)₄ were 18 times higher (both IC₅₀ about 70 picomolar) than that of the c(RGDfK) peptide (IC₅₀=1.3 nanomolar). Facile access to tetrameric conjugates and the possibility of radiolabeling with therapeutic and diagnostic radionuclides render DOTPI suitable for application in peptide receptor radionuclide imaging (PRRI) and therapy (PRRT).     

Determination of impurities in marbles from different deposits in Yugoslavia by activation analysis

Impurities in marbles from the deposits in Petrovac na Mlavi, near Gostivar (Duf and Sušički Most) and Venčac in Yugoslavia have been determined by activation analysis. The impurities of Na, Mn and Cu were determined from the characteristic photopeaks with γ-energies of 1.38 and 2.78 MeV (²⁴Na); 0.511 MeV (⁶⁴Cu) and 0.850 MeV (⁵⁶Mn), and from the corresponding half-lives of these radioisotopes. The concentrations of Mn, Na and Cu were also determined in every marble sample.     

Studies in heavy ion activation analysis

¹⁸O induced radioactivation may be used for the trace detection of¹H via¹H (¹⁸O, n)¹⁸F. Matrices in which this reaction is interference-free include: Al, Si, S, K, Ti, V, Ni, Cu and Zn. However, due to numerous radioisotopes created at the bombarding energies used (E≥51 MeV), a post-irradiation chemical separation of¹⁸F is required.¹⁸O activation also appears as a promising means for the trace determination of S[S(¹⁸O, x)⁴⁷V], Si[Si(¹⁸O, x)^43–44Sc] and B[B(¹⁸O, x)³⁷Mg]. Part I: in Journal of Radioanalytical Chemistry, 53 (1979) 181.     

Applications of “Hot” and “Cold” Bis(thiosemicarbazonato) Metal Complexes in Multimodal Imaging

The applications of coordination chemistry to molecular imaging has become a matter of intense research over the past 10 years. In particular, the applications of bis(thiosemicarbazonato) metal complexes in molecular imaging have mainly been focused on compounds with aliphatic backbones due to the in vivo imaging success of hypoxic tumors with PET (positron emission tomography) using ⁶⁴CuATSM [copper (diacetyl‐bis(N4‐methylthiosemicarbazone))]. This compound entered clinical trials in the US and the UK during the first decade of the 21^st century for imaging hypoxia in head and neck tumors. The replacement of the ligand backbone to aromatic groups, coupled with the exocyclic N's functionalization during the synthesis of bis(thiosemicarbazones) opens the possibility to use the corresponding metal complexes as multimodal imaging agents of use, both in vitro for optical detection, and in vivo when radiolabeled with several different metallic species. The greater kinetic stability of acenaphthenequinone bis(thiosemicarbazonato) metal complexes, with respect to that of the corresponding aliphatic ATSM complexes, allows the stabilization of a number of imaging probes, with special interest in “cold” and “hot” Cu(II) and Ga(III) derivatives for PET applications and ¹¹¹In(III) derivatives for SPECT (single‐photon emission computed tomography) applications, whilst Zn(II) derivatives display optical imaging properties in cells, with enhanced fluorescence emission and lifetime with respect to the free ligands. Preliminary studies have shown that gallium‐based acenaphthenequinone bis(thiosemicarbazonato) complexes are also hypoxia selective in vitro, thus increasing the interest in them as new generation imaging agents for in vitro and in vivo applications.     

Automated production of 64Cu prepared by 18?MeV cyclotron

⁶⁴Cu (T_1/2?=?12,7?h, ??^? 37,1?%, ??⁺ 17,9?%, EC 41?%) is a useful radioisotopes for positron emission tomography radiopharmaceutical. We used the reaction route ⁶⁴Ni(p,n)⁶⁴Cu for the ⁶⁴Cu preparation. A basic disadvantage of this route, a high price of the enriched target material, was eliminated by using very simple recycling procedure. Compact solid target irradiation system was installed at the end of the external beam line of the IBA Cyclone 18/9 cyclotron. In this paper, the irradiation of ⁶⁴Ni target and separation of ⁶⁴Cu from a target material is described. The separation was achieved by anion exchange chromatography with HCl as a elution solution. The distribution ratio for different HCl concentrations on Bio-Rad AG1-X8 and elution profile of ⁶⁴Cu were investigated. ⁶⁴Cu production rate for 100?mg ⁶⁴Ni of 99.09?% purity (ISOFLEX) on gold target was 104?MBq/??Ah. The activity of the product was checked by ionisation chamber (Curiementor), gamma spectrometry using a HPGe detector and liquid scintillation counting using the triple-to-double coincidence ratio method. The separation process of ⁶⁴Cu was made in a home-made separation module.     

Thin-target excitation functions and optimization of simultaneous production of NCA copper-64 and gallium-66,67 by deuteron induced nuclear reactions on a natural zinc target

Copper-64 is a radionuclide suitable for labeling of a wide range of radiopharmaceuticals for PET imaging, as well as systemic or local radioimmunotherapy of tumors. Among the possible methods for cyclotron production of No Carrier Added (NCA) ⁶⁴Cu (⁶¹Cu), we investigated the deuteron irradiation on natural Zn target, via (d,axn) and (d,2pxn) nuclear reactions. This paper reports the preliminary results about the experimental determination and theoretical calculation of thin-target excitation functions in the energy range up to 19 MeV for ⁶¹Cu, ⁶⁴Cu, ⁶⁶Ga, ⁶⁷Ga, ⁶⁵Zn and ^69mZn. A fast selective radiochemical separation of NCA ⁶⁴Cu from Zn target and Ga radionuclides, with quality control tests is described too.     

67Cu Production Capabilities: A Mini Review

Is the ⁶⁷Cu production worldwide feasible for expanding preclinical and clinical studies? How can we face the ingrowing demands of this emerging and promising theranostic radionuclide for personalized therapies? This review looks at the different production routes, including the accelerator- and reactor-based ones, providing a comprehensive overview of the actual ⁶⁷Cu supply, with brief insight into its use in non-clinical and clinical studies. In addition to the most often explored nuclear reactions, this work focuses on the ⁶⁷Cu separation and purification techniques, as well as the target material recovery procedures that are mandatory for the economic sustainability of the production cycle. The quality aspects, such as radiochemical, chemical, and radionuclidic purity, with particular attention to the coproduction of the counterpart ⁶⁴Cu, are also taken into account, with detailed comparisons among the different production routes. Future possibilities related to new infrastructures are included in this work, as well as new developments on the radiopharmaceuticals aspects.     

Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor

Identification of tumors which over-express Epidermal Growth Factor Receptor (EGFR) is important in selecting patients for anti-EGFR therapies. Enzymatic bioconjugation was used to introduce positron-emitting radionuclides (⁸⁹Zr, ⁶⁴Cu) into an anti-EGFR antibody fragment for Positron Emission Tomography (PET) imaging the same day as injection. A monovalent antibody fragment with high affinity for EGFR was engineered to include a sequence that is recognized by the transpeptidase sortase A. Two different metal chelators, one for ⁸⁹Zr^IV and one for ⁶⁴Cu^II, were modified with a N-terminal glycine to enable them to act as substrates in sortase A mediated bioconjugation to the antibody fragment. Both fragments provided high-quality PET images of EGFR positive tumors in a mouse model at 3 hours post-injection, a significant advantage when compared to radiolabeled full antibodies that require several days between injection of the tracer and imaging. The use of enzymatic bioconjugation gives reproducible homogeneous products with the metal complexes selectively installed on the C-terminus of the antibody potentially simplifying regulatory approval.

Enzymatic bioconjugation to introduce positron-emitting radionuclides (⁸⁹Zr, ⁶⁴Cu) into an anti-EGFR antibody fragment allows same day imaging with positron emission tomography.     

An Eighteen‐Membered Macrocyclic Ligand for Actinium‐225 Targeted Alpha Therapy

The 18‐membered macrocycle H₂macropa was investigated for ²²⁵Ac chelation in targeted alpha therapy (TAT). Radiolabeling studies showed that macropa, at submicromolar concentration, complexed all ²²⁵Ac (26 kBq) in 5 min at RT. [²²⁵Ac(macropa)]⁺ remained intact over 7 to 8 days when challenged with either excess La³⁺ ions or human serum, and did not accumulate in any organ after 5 h in healthy mice. A bifunctional analogue, macropa‐NCS, was conjugated to trastuzumab as well as to the prostate‐specific membrane antigen‐targeting compound RPS‐070. Both constructs rapidly radiolabeled ²²⁵Ac in just minutes at RT, and macropa‐Tmab retained >99 % of its ²²⁵Ac in human serum after 7 days. In LNCaP xenograft mice, ²²⁵Ac‐macropa‐RPS‐070 was selectively targeted to tumors and did not release free ²²⁵Ac over 96 h. These findings establish macropa to be a highly promising ligand for ²²⁵Ac chelation that will facilitate the clinical development of ²²⁵Ac TAT for the treatment of soft‐tissue metastases.     

Study of secondary implantation of radioisotopes during alpha-particle irradiation

This work presents the recoil and secondary implantation of radioisotopes at different bombarding energies in the range of ~?13 to ~?40 MeV by using an α-particle beam of 50 MeV irradiating a stack of Ag, Ni and Ti metal foils. Activation cross-sections for the produce radioisotopes were calculated and confronted with literature data. The implanted activity is presented as a function of the primary beam energy for six produced radioisotopes ⁵⁷Ni, ⁵⁷Co, ⁶⁵Zn, ⁵¹Cr, ⁴⁸V and ⁴⁶Sc. The use of each of these radioisotopes in engineering experiments based on the nano-thin layer activation is discussed.

     

Current status and future plan for the production of radioisotopes using HANARO Research Reactor

The Korea Atomic Energy Research Institute (KAERI) completed the High-flux Advanced Neutron Application Reactor (HANARO) in 1995 and the radioisotope production facilities(RIPF) in 1997. Many devices and handling tools were developed and applied for the production of radioisotopes. Emphasis on RI production plan was placed on the development of new radiopharmaceuticals, the development of new radiation sources for industrial use and the steady production of selected radioisotopes. The selected items are ¹⁶⁶Ho-based pharmaceuticals, fission ⁹⁹Mo/^99mTc generators, and products of ¹³¹I and ¹⁹²Ir and ⁶⁰Co sources for industrial use. Now KAERI regularly produces radioisotopes (¹³¹I, ^99mTc, ¹⁶⁶Ho, ¹⁹²Ir, ⁶⁰Co etc.) and labeled compounds including ^99mTc cold kits. Newly developed therapeutic agents are a ¹⁶⁶Ho-chitosan complex for liver cancer treatment, a ¹⁶⁶Ho patch for skin cancer treatment and devices such as the stent and balloon for the prevention against restenosis of the coronary artery. Feasibility studies on the installation of a ^99mTc generator loading facility and on ⁶⁰Co production for food irradiation were finished. The ¹⁹²Ir sealed source assembly for NDT has been supplied to domestic users since May 2001. The fission moly process, separation process of non-sealed sources (¹²⁵I, ³³P, ⁸⁹Sr, ¹⁵³Sm, ¹⁸⁸Re) and fabrication process of sealed sources (¹⁶⁹Yb, ⁷⁵Se) are also under development. For the quality assurance of our final products, we obtained ISO certification in 2000. We are carrying out a feasibility study on a new research reactor for the stable supply of radioisotopes in Korea.     

Krypton isotopic signature study of the primary coolant of CANDU nuclear power plant

To support interpretation of observed atmospheric krypton radioisotopes, a database of krypton radioisotope in the primary coolant of CANDU reactors has been established. This database is comprised of 40,000 records of high-quality ⁸⁹Kr, ⁸⁷Kr, ⁸⁸Kr and ^85mKr analyses. Records from the database were retrieved by a specifically designed data-mining module and subjected to further analysis. Results from the analysis were subsequently used to study isotopic ratios of observed krypton radioisotopes in the CANDU reactor primary coolant. These studies provided practical information on the characterization of CANDU reactor krypton radioisotope, which can potentially be used to discriminate between reactor effluent and fuel reprocessing for nuclear safeguard ⁸⁵Kr monitoring applications (Kalinowski et al., J Environ Radioact 73:203, 2004). The study also has some potential application to Fissile material cut-off treaty.     

Chemical and Physical Characterisation of Macroaggregated Human Serum Albumin: Strength and Specificity of Bonds with 99mTc and 68Ga

Background: Macroaggregated human serum albumin (MAA) properties are widely used in nuclear medicine, labelled with ^99mTc. The aim of this study is to improve the knowledge about the morphology, size, dimension and physical–chemical characteristics of MAA and their bond with ^99mTc and ⁶⁸Ga. Methods: Commercial kits of MAA (Pulmocis^®) were used. Characterisation through experiments based on SEM, DLS and Stokes’ Law were carried out. In vitro experiments for Langmuir isotherms and pH studies on radiolabelling were performed and the stability of the radiometal complex was verified through competition reactions. Results: The study settles the MAA dimension within the range 43–51 μm. The Langmuir isotherm reveals for [^99mTc]MAA: Bmax (46.32), h (2.36); for [⁶⁸Ga]MAA: Bmax (44.54), h (0.893). Dual labelling reveals that MAA does not discriminate different radioisotopes. Experiments on pH placed the optimal pH for labelling with ^99mTc at 6. Conclusion: Radiolabelling of MAA is possible with high efficiency. The nondiscriminatory MAA bonds make this drug suitable for radiolabelling with different radioisotopes or for dual labelling. This finding illustrates the need to continue investigating MAA chemical and physical characteristics to allow for secure labelling with different isotopes.